🔎 Trials Near Me

Home › Dermatomyositis › Massachusetts

Pag-aaral pangklinika para sa Dermatomyositis sa Massachusetts

5 pag-aaral para sa Dermatomyositis ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  • Research Site, Boston
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06455449

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
Nagre-recruitPhase 2/3
Edad 6 hanggang 75 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06154252

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  • Brigham and Women's Hospital, Boston
  • CTC - Brigham & Women's Hospital, Boston
  • CTH - Brigham & Women's Hospital, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05895786

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  • Brigham And Womens Hospital, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT07115745

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.